ただし、追加料金で日本語のレポートが入手できる場合もある。
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Active Pharmaceutical Ingredients (API) Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Breakup by Drug Type
5.5 Market Breakup by Type of Manufacturer
5.6 Market Breakup by Type of Synthesis
5.7 Market Breakup by Therapeutic Application
5.8 Market Breakup by Region
5.9 Market Forecast
5.10 SWOT Analysis
5.10.1 Overview
5.10.2 Strengths
5.10.3 Weaknesses
5.10.4 Opportunities
5.10.5 Threats
5.11 Value Chain Analysis
5.12 Porters Five Forces Analysis
5.12.1 Overview
5.12.2 Bargaining Power of Buyers
5.12.3 Bargaining Power of Suppliers
5.12.4 Degree of Competition
5.12.5 Threat of New Entrants
5.12.6 Threat of Substitutes
5.13 Price Analysis
5.13.1 Price Indicators
5.13.2 Price Structure
6 Market Breakup by Drug Type
6.1 Innovative Active Pharmaceutical Ingredients (API)
6.2 Generic Active Pharmaceutical Ingredients (API)
7 Market Breakup by Type of Manufacturer
7.1 Captive Manufacturers
7.2 Merchant API Manufacturers
7.2.1 Innovative Merchant API Manufacturers
7.2.2 Generic Merchant API Manufacturers
8 Market Breakup by Type of Synthesis
8.1 Synthetic Active Pharmaceutical Ingredients (API)
8.1.1 Market Breakup by Type
8.1.1.1 Innovative Synthetic APIs
8.1.1.2 Generic Synthetic APIs
8.2 Biotech Active Pharmaceutical Ingredients (API)
8.2.1 Market Breakup by Type
8.2.1.1 Innovative Biotech APIs
8.2.1.2 Biosimilars
8.2.2 Market Breakup by Product
8.2.2.1 Monoclonal Antibodies
8.2.2.2 Vaccines
8.2.2.3 Cytokines
8.2.2.4 Fusion Proteins
8.2.2.5 Therapeutic Enzymes
8.2.2.6 Blood Factors
8.2.3 Market Breakup by Expression System
8.2.3.1 Mammalian Expression Systems
8.2.3.2 Microbial Expression Systems
8.2.3.3 Yeast Expression Systems
8.2.3.4 Transgenic Animal Systems
8.2.3.5 Others
9 Market Breakup by Therapeutic Application
9.1 Oncology
9.2 Cardiovascular and Respiratory
9.3 Diabetes
9.4 Central Nervous System Disorders
9.5 Neurological Disorders
9.6 Others
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.2 Canada
10.2 Europe
10.2.1 Germany
10.2.2 France
10.2.3 United Kingdom
10.2.4 Italy
10.2.5 Spain
10.2.6 Russia
10.2.7 Others
10.3 Asia Pacific
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 South Korea
10.3.5 Australia
10.3.6 Indonesia
10.3.7 Others
10.4 Latin America
10.5 Middle East and Africa
11 API Manufacturing Process
11.1 Product Overview
11.2 Raw Material Requirements
11.3 Manufacturing Process
11.4 Key Success and Risk Factors
12 Competitive Landscape
12.1 Market Structure
12.2 Key Players
12.3 Profiles of Key Players
12.3.1 Pfizer, Inc.
12.3.2 Novartis International AG
12.3.3 Sanofi
12.3.4 Boehringer Ingelheim
12.3.5 Bristol-Myers Squibb
12.3.6 Teva Pharmaceutical Industries Ltd.
12.3.7 ELI Lilly and Company
12.3.8 GlaxoSmithKline
12.3.9 Merck & Co., Inc.
12.3.10 Abbvie Inc